-
FDA Approves Stem-cell Trial for ALS Patients at UM
NSI-566/ALS trial principal investigator, Eva Feldman, M.D., Ph.D., is interviewed for this article announcing FDA approval of Neuralstem’s ALS Phase II trial.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.